RPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Royalty Pharma's enterprise value is $17,458 Mil. Royalty Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $1,887 Mil. Therefore, Royalty Pharma's EV-to-EBITDA for today is 9.25.
The historical rank and industry rank for Royalty Pharma's EV-to-EBITDA or its related term are showing as below:
During the past 7 years, the highest EV-to-EBITDA of Royalty Pharma was 61.44. The lowest was 7.37. And the median was 18.63.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-27), Royalty Pharma's stock price is $28.00. Royalty Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.520. Therefore, Royalty Pharma's PE Ratio for today is 11.11.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Royalty Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | - | 14.70 | 18.19 | 61.60 | 11.13 |
Royalty Pharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 61.60 | 30.73 | 32.79 | 35.74 | 11.13 |
For the Biotechnology subindustry, Royalty Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Royalty Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's EV-to-EBITDA falls into.
Royalty Pharma's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 17458.035 | / | 1887.275 | |
= | 9.25 |
Royalty Pharma's current Enterprise Value is $17,458 Mil.
Royalty Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,887 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (NAS:RPRX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Royalty Pharma's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 28.00 | / | 2.520 | |
= | 11.11 |
Royalty Pharma's share price for today is $28.00.
Royalty Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.520.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Royalty Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Rory B Riggs | director | 65 RAILROAD AVE, RIDGEFIELD NJ 07657 |
Avara Management Ltd | 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
Terrance P. Coyne | officer: EVP & CFO | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Pablo G. Legorreta | director, officer: CEO, Chairman of the Board | 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022 |
George W. Lloyd | officer: EVP, Investments & GC | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Marshall Urist | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Mario Germano Giuliani | director, 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
James F. Reddoch | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Nogra Group Sicaf Sif Gg Strategic | 10 percent owner | C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Nogra Group Sicaf - Sif S.a. | 10 percent owner | 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Catherine M. Engelbert | director | 110 NORTH CARPENTER STREET, CHICAGO IL 60607 |
Errol B Desouza | director | 215 COLLEGE ROAD, PARAMUS NJ 07652 |
Henry A Fernandez | director | MSCI INC., 88 PINE STREET, NEW YORK NY 10005 |
Gregory Norden | director | 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005 |
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Marketwired • 07-17-2023
By GuruFocus Research GuruFocus Editor • 01-28-2023
By GuruFocus Research GuruFocus Editor • 02-20-2023
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 04-17-2023
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 03-27-2023
By GuruFocus Research • 05-26-2023
By Stock market mentor Stock market mentor • 01-09-2023
By sperokesalga sperokesalga • 05-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.